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Introduction
 Cancer is the leading cause of death in Korea since 
1983 (Statistics Korea,2012) and is associated with the 
largest disease burden (Yoon et al., 2007; Kimman et 
al., 2012). Of cancers, lung cancer has one of the highest 
fatality rates, and is the leading cause of cancer-related 
mortality in the South Korea (Shin et al., 2012) and 
worldwide (Jemal et al., 2011). The latest statistics showed 
that numbers of incident lung cancer cases were 20,711 
(out of 202,053, 71% male), deaths were 15,623 (out of 
72,046, 73% male), and prevalent lung cancer cases were 
43,564 (out of 960,654, 66% male) during 2010 in Korea 
(Jung et al., 2013). In Korea for 2010, 72,046 cancer deaths 
were reported, with lung cancer accounting for 28.2% of 
all deaths, the highest cancer fatality rate in both male 
and female. Five-year survival rates for lung cancer are 
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Abstract
 Background: In Korea, the National Health Insurance program has initiated various copayment policies 
over a decade in order to alleviate patient financial burden. This study investigated healthcare spending and 
utilization in the last 12 months of life among patients who died with lung cancer by various copayment policy 
windows. Materials and Methods: We performed a retrospective cohort study using nationwide lung cancer 
health insurance claims data from 2002 to 2012. We used descriptive and multivariate methods to compare 
spending measured by total costs, payer costs, copayments, and utilization (measured by length of stay or 
outpatient days). Using 1,4417,380 individual health insurance claims (inpatients: 673,122, outpatients: 744,258), 
we obtained aggregated healthcare spending and utilization of 155,273 individual patient (131,494 inpatient and 
103,855 outpatient) records. Results: National spending and utilization is growing, with a significant portion of 
inpatient healthcare spending and utilization occurring during the end-of-life period. Specifically, inpatients were 
more likely to have more spending and utilization as they got close to death. As coverage expanded, copayments 
decreased, but overall costs increased due to increased utilization. The trends were the same in both inpatient 
and outpatient services. Multivariate analysis confirmed the associations. Conclusions: We found evidence of the 
higher end of life healthcare spending and utilizations in lung cancer patients occurring as coverage expanded. 
The practice pattern within a hospital might be influenced by coverage policies. Health policy makers should 
consider initiating various health policies since these influence the long-term outcomes of service performance 
and overall healthcare spending and utilization. 
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under 20% and average survival is about six months, one 
of the lowest survival rates, because most patients have 
advanced-stage lung cancer at their initial diagnosis (Jung 
et al., 2013).
 Healthcare in general and cancer care in particular is 
very expensive (Meropol and Schulman, 2007). Moreover, 
advancement of new cancer diagnostics and treatments 
contributed to rising costs for cancer care as well (Sullivan 
et al., 2011). Evidence from other countries shows costs 
rising at a rate outpacing inflation and consuming an 
increasing share of expenditures at all budgetary levels 
in almost all countries. Simultaneously there are rising 
questions of cost-benefit for the proven interventions by 
individual or society level (Sullivan et al., 2011). It is ideal 
that more effective and less toxic cares should be initiated , 
but the price of those innovations are required further costs 
unfortunately (DiMasi et al., 2003). Furthermore, health 
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care utilization is associated with dying, suggesting that 
a large proportion of expenditures occur in the last few 
months prior to death (Lubitz and Prihoda, 1984; McCall, 
1984; Scitovsky, 1984). In the United States, healthcare 
spending in the last year of life consumes approximately 
27% of the Medicare budget and has done so consistently 
over the past decades (Lubitz and Riley, 1993).
 The Korean government introduced mandatory social 
health insurance for employees of large corporations in 
1977 and achieved universal health insurance program 
in 1988 (Jeon and Kwon, 2013). However, even with the 
universal coverage through the mandatory National Health 
Insurance (NHI), only 58.2% of total health expenditures 
are associated with the public sector, comparing to 72.2% 
for OECD countries as of 2010 (OECD, 2012). Korea also 
faces with health care spending issue that the highest rate 
of growth, more than twice the OECD average (OECD, 
2012). NHI members still need to pay high out-of-pocket 
payment (copayments) and full payment for uncovered 
services, to some extent related to fee-for-service 
reimbursement system that might supplier induces demand 
and relatively fast adoption of state-of-art technologies 
(Kwon, 2009).
 Since cancer is associated with expensive treatments, 
drugs, and other diagnostic procedures, NHI initiated 
various copayment policies over a decade to alleviate 
patients’ financial burden. In January 2004, NHI initiated 
a copayment policy that limits copayments to 20% for 
cancer patients in outpatient services where normal copay 
is 50%. In September 2005, the coverage was expanded 
to 10% copayments for both inpatient and outpatient 
services for cancer patients. In December 2009, the 
coverage was expanded again to 5% copayments for 
both inpatient and outpatient services. The landmark 
RAND Health Insurance Experiment conducted in the late 
1970s randomized families to different health insurance 
plans that varied in their cost-sharing. They found that 
families subjected to higher cost-sharing reduced the use 
of health services virtually across the board, including 
fewer physician visits and fewer adult inpatient hospital 
stays, less preventive and non-preventive care, and less 
use of both effective and non-effective care (Leibowitz 
et al., 1985; Lohr et al., 1986; Newhouse, 2004). There 
are similar findings in a pediatric population (Sen et al., 
2012).
 The effects of increased cost-sharing on use of 
health services are well-documented, but the impact of 
expansion of insurance coverage on healthcare spending 
and utilizations is less researched (You et al., 2013). In the 
roughly 10 years since the policy was first implemented, 
there has been no comprehensive nationwide investigation 
into the effect of the coverage expansions. This study 
aims to fill this gap by exploring how expanded national 
insurance coverage during the past decade impacted health 
care service spending and utilization at the end of life for 
lung cancer patients.
Materials and Methods
Data collection and construction
 We collected all nationwide lung cancer inpatient and 
outpatient claims data between 2002 and 2012 to investigate 
health care spending, utilizations, and associations with 
copayment policies. Lung cancer patients were defined 
by ICD-10 (International Classification of Diseases-10) 
codes C33-C34. This dataset contained health insurance 
claim details including total inpatient/outpatient costs, 
patients’ copayments, and payer costs. Furthermore, length 
of stay, outpatient days for each inpatient, and outpatient 
claims were included. Other variables include admission/
outpatient visit date, date of death, age, sex, ICU days and 
days on ventilator during hospitalization. 
 To measure the severity of disease, we calculated the 
progression of lung cancer using the dataset. With the 
inpatient and outpatient records of 2003, we searched 
2002 claims. If a patient has any utilization record in 
2002, we assumed that the patient was diagnosed with 
cancer in 2002. If a patient has no records in 2002, we 
assumed that the patient was newly diagnosed in the year 
2003. Likewise, using all records in 2004, we searched 
all claim records of year 2002 and 2003. If a patient has 
any records in 2002 or 2003, we assumed the patient was 
diagnosed in 2002 or 2003. If a patient has no record in 
2002 and 2003 then we assumed the patient was newly 
diagnosed in 2004. Using the method above, we calculated 
all patients’ year of diagnosis. 
 Since the dataset is health insurance claim data, we 
included only patients who died with lung cancer and 
transposed the dataset to a retrospective cohort design with 
the baseline as death of each patient. To investigate secular 
trends and factors influencing health care utilization and 
spending of lung cancer patients, we aggregated each 
patient’s spending and utilization by three month intervals 
up to 12 months before death [3 months before death, 3-6 
months before death, 6-9 months before death, and 9-12 
months before death]. We selected the span of 12 months 
before death to see pure end-of-life lung cancer spending 
and utilization. 
 In Korea, the fee for services (FFS) catalogue is 
negotiated by the government, providers, and other 
stakeholders every year. We discounted all inpatient 
and outpatient costs to 2002 levels using each year’s 
negotiated FFS catalogue. To investigate the copayments 
policy impact, we created dummy variable such that each 
patient’s aggregated health care spending and utilization 
information fell within specific policy periods. The yearly 
mean of the FX rate was 1USD=1251.20 KRW in year 
2002 (cf. The yearly mean of FX rate of year 2012 1 
USD=1126.88 KRW). 
 Since year 2002 is baseline point of measuring each 
patient’s cancer progression, we deleted the year 2002 
dataset. Furthermore, we excluded patients diagnosed 
with lung cancer more than five years prior, assuming 
those patients did not have severe lung cancer. Finally 
we excluded patients with inpatient total costs less than 
300,000 KRW and outpatient costs less than 100,000 
KRW, assuming those hospitalization and outpatient 
visits were occasional. Using 1,4417,380 individual 
health insurance claims (inpatients: 673,122, outpatients: 
744,258), we obtained aggregated healthcare spending and 
utilization of total 155,273 patients’ (131,494 inpatient 
and 103,855 outpatients) records.
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Statistical Analysis
 We first examined characteristics of nationwide lung 
cancer patients at their time of death by inpatient and 
outpatient status. Then we examined trends of health 
care spending and utilizations by three month intervals 
up 12 months before death, by their inclusion in various 
copayment policy windows. Student’s t-test and analysis 
of variance were used to compare mean spending and 
utilization. After adjusting for patient demographics and 
other potential confounders, we used multivariate analysis 
to investigate the effect of copayment policy on health 
care spending and utilizations. We used generalized linear 
models for each patient’s three month intervals before 
death. SAS 9.2 (SAS Institute, Cary, NC) was used for all 
calculations and analyses. All statistical tests were two-
tailed, and we rejected null hypotheses of no difference 
if p-values were less than .05, or, equivalently, if the 95% 
CIs of risk point estimates excluded 1.
Results 
 An overall trend of healthcare spending and utilization 
by lung cancer patients is presented in Figure 1. Both 
discounted spending and utilization gradually increased 
over the past decade. 
 Table 1 shows baseline characteristics of lung cancer 
patients nationwide. Since our study investigates spending 
and utilization retrospectively from time at death, 155,273 
patients met our cohort definition. This included 131,494 
inpatients and 103,885 outpatients. Most patients were 
male and mean age was about 70. More than 80% of 
patients died during their diagnosis year (progression =0, 
54.2%) or in the following year (progression =1, 29.6%).
 Table 2 depicts overall lung cancer episode spending 
and utilization, and three month intervals until 12 months 
before death by both inpatient and outpatient services. A 
significant portion of inpatient healthcare spending and 
utilization occurs during the end of life. Most patients 
were hospitalized (105,121 out of 131,494) in the three 
months before death. This end-of-life period spending and 
utilization were higher than other periods. The likelihood 
of inpatient hospitalization gradually increases as patients 
get close to death. However, the trend in outpatient cost 
is completely different from the inpatient. Although the 
number of patients increased close to death, outpatient 
spending and utilization decreased with approaching 
death. All differences were statistically significant.
 The results of bivariate analysis of each outcome 
variable by specific copayment policy periods are 
presented in Table 3. As noted, inpatient costs increased 
as patients get close to their death and utilization (defined 
as length of stay) also increased. In contrast, outpatient 
spending and utilizations gradually decreased until close 
to death. Especially for policy impact, both inpatient and 
outpatient copayments significantly decreased as national 
health insurance coverage expanded, while the total costs 
and payer burden significantly increased.
 The results of the multivariate generalized linear 
model analysis are presented in Table 4. Inpatient model 
results show that total costs and payer costs increased 
Figure 1. Discounted Healthcare Spending and 
Utilization among Nationwide Lung Cancer Patients
Table 1. Characteristics of Korean Lung Cancer 
Patients at Their Time of Death
 Total  Inpatients  Outpatients 
 N % N % N %
No. of Patients 155,273 100% 131,494 100% 103,855 100%
Sex      
   Male 114,864 74.00% 98,833 75.20% 78,448 75.50%
   Female 40,409 26.00% 32,661 24.80% 25,407 24.50%
Years of Cancer Progression at Death
   0 84,140 54.20% 68,399 52.00% 47,456 45.70%
   1 45,948 29.60% 41,124 31.30% 35,054 33.80%
   2 14,063 9.10% 12,802 9.70% 11,765 11.30%
   3 5,459 3.50% 4,972 3.80% 4,728 4.60%
   4 2,525 1.60% 2,385 1.80% 2,293 2.20%
   5 3,138 2.00% 1,812 1.40% 2,559 2.50%
Age* 69.08 10.9 68.93 10.66 67.5 10.53
* Mean, SD; ** = Death at diagnosed year
Table 2. Healthcare Spending and Utilization by Lung Cancer Patients in Their Last Year of Life by Three 
Month Intervals Before Death
 N Total Costs [KRW] P Copayments [KRW] P Payer Costs [KRW] P LOS [Days] P
 Mean SD Mean SD Mean SD Mean SD
Inpatients 3 Month Before Death 105,121 5,843,475 5,614,031 <.0001 644,051 586,430 <.0001 5,199,425 5,161,958 <.0001 29.11 21.55 <.0001
 3-6 Months Before Death 53,559 4,876,716 4,677,016  558,727 544,558  4,317,989 4,250,238  23.68 23.44 
 6-9 Months Before Death 36,194 4,444,676 4,004,029  512,461 479,444  3,932,214 3,638,342  19.71 20.21 
 9-12 Months Before Death 26,417 4,405,837 3,875,803  513,324 469,750  3,892,513 3,519,237  18.57 19.25 
Outpatients 3 Month Before Death 66,215 1,049,578 1,361,799 <.0001 121,419 176,617 <.0001 928,160 1,253,435 <.0001 4.66 5.47 <.0001
 3-6 Months Before Death 57,323 1,538,014 1,913,413  175,371 250,673  1,362,643 1,759,557  5.92 6.63 
 6-9 Months Before Death 44,547 1,636,352 2,045,174  188,645 269,921  1,447,707 1,880,674  5.96 6.75 
 9-12 Months Before Death 34,982 1,708,667 2,153,421  200,710 291,513  1,507,958 1,974,868  6.09 6.94 
Inpatient Episode 131,494 11,634,031 12,226,039  1,346,122 1,380,773  10,287,909 11,071,139  53.6 61.5 
Outpatient Episode 103,855 4,902,526 8,161,963  599,036 949,589  4,303,490 7,435,208  18.8 23.8 
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Table 3. Healthcare Spending and Utilization by Copayment Policies and three Month Intervals before Death 
for Both Inpatients, Outpatients
  After 2009. 12. 2005.09. - 2009. 11. 2004. 01. - 2005. 08. Before 2003. 12. P
  Mean SD Mean SD Mean SD Mean SD 
Inpatients Total Costs 3 Month Before Death 6,960,077 6,366,614 5,956,633 5,488,786 3,858,734 3,660,987 3,514,449 3,353,130 <.0001
[KRW] 3-6 Months Before Death 5,542,900 5,098,022 5,025,741 4,735,171 3,518,234 3,355,568 3,446,606 3,394,279 <.0001
 6-9 Months Before Death 5,087,229 4,463,832 4,542,220 3,993,057 3,314,046 2,940,541 3,271,446 2,825,347 <.0001
 9-12 Months Before Death 5,081,499 4,401,401 4,500,512 3,845,115 3,367,891 2,768,522 3,268,510 2,866,174 <.0001
Inpatients Copayments 3 Month Before Death 500,123 406,383 685,464 599,643 829,931 765,607 747,120 689,195 <.0001
[KRW] 3-6 Months Before Death 414,119 376,593 580,688 537,992 764,260 702,401 736,783 698,319 <.0001
 6-9 Months Before Death 370,041 341,402 519,533 457,377 721,813 618,058 697,334 585,043 <.0001
 9-12 Months Before Death 363,894 333,278 511,105 440,950 729,428 582,098 695,585 592,732 <.0001
Inpatients Payer Costs 3 Month Before Death 6,459,954 6,010,075 5,271,169 4,918,101 3,028,803 2,899,081 2,767,329 2,666,184 <.0001
[KRW] 3-6 Months Before Death 5,128,782 4,772,407 4,445,054 4,223,482 2,753,974 2,657,558 2,709,823 2,698,401 <.0001
 6-9 Months Before Death 4,717,189 4,172,069 4,022,687 3,560,389 2,592,232 2,327,974 2,574,112 2,242,894 <.0001
 9-12 Months Before Death 4,717,604 4,116,269 3,989,407 3,424,547 2,638,463 2,191,692 2,572,925 2,276,029 <.0001
Inpatients LOS 3 Month Before Death 31.25 22.33 29.89 21.58 24.46 19.55 22.9 18.55 <.0001
[Days] 3-6 Months Before Death 25.06 24.53 24.29 23.69 20.29 20.38 20.21 21.04 <.0001
 6-9 Months Before Death 21.21 22 19.97 20.15 16.88 16.77 17.15 17.41 <.0001
 9-12 Months Before Death 20.13 21.18 18.71 19.19 16.18 15.93 16.31 16.68 <.0001
Outpatients Total Costs 3 Month Before Death 1,189,124 1,490,691 1,124,376 1,405,830 717,231 956,189 539,338 704,514 <.0001
[KRW] 3-6 Months Before Death 1,706,583 2,037,338 1,677,607 2,011,024 1,063,957 1,379,169 776,698 1,018,943 <.0001
 6-9 Months Before Death 1,817,868 2,198,977 1,786,471 2,145,523 1,121,813 1,426,424 853,784 1,112,699 <.0001
 9-12 Months Before Death 1,903,930 2,314,689 1,870,635 2,260,108 1,171,675 1,522,983 894,975 1,220,866 <.0001
Outpatients Copayments 3 Month Before Death 66,668 85,505 121,762 146,032 180,297 215,486 275,426 367,533 <.0001
[KRW] 3-6 Months Before Death 91,465 109,565 176,588 203,471 267,425 302,232 400,032 528,075 <.0001
 6-9 Months Before Death 96,953 117,336 187,157 217,683 285,429 308,285 440,421 577,531 <.0001
 9-12 Months Before Death 101,640 122,952 197,228 231,326 300,725 328,683 460,421 629,728 <.0001
Outpatients Payer Costs 3 Month Before Death 1,122,457 1,420,404 1,002,614 1,269,212 536,934 748,282 263,912 340,329 <.0001
[KRW] 3-6 Months Before Death 1,615,118 1,940,663 1,501,019 1,815,941 796,532 1,083,251 376,665 493,184 <.0001
 6-9 Months Before Death 1,720,915 2,094,858 1,599,315 1,936,369 836,384 1,124,459 413,362 537,758 <.0001
 9-12 Months Before Death 1,802,290 2,204,466 1,673,407 2,038,104 870,949 1,201,706 434,554 593,801 <.0001
Outpatients Days 3 Month Before Death 4.19 5.04 5.02 5.67 4.76 5.66 4.64 5.73 <.0001
[Days] 3-6 Months Before Death 5.38 6.14 6.35 6.74 6.02 7.05 5.78 7.21 <.0001
 6-9 Months Before Death 5.49 6.28 6.31 6.78 5.97 7.12 5.99 7.67 <.0001
 9-12 Months Before Death 5.66 6.63 6.45 6.98 6.1 7.24 5.81 7.35 <.0001
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Table 4. Multivariate Analysis to Investigate Impact of Copayment Policies on Healthcare Spending and Utilization 
for Lung Cancer Patients at end of Life
 Total Costs Copayments Payer Costs LOS/Outpatient days
 Est. [KRW] P Est. [KRW] P Est. [KRW] P Est. [Days] P
Inpatient 3 Month Before Death After 2009. 12. 993,758 <.0001 -684,118 <.0001 1,677,876 <.0001 2.45 <.0001
  2005.09. - 2009. 11. 946,705 <.0001 -326,423 <.0001 1,273,128 <.0001 2.78 <.0001
  2004. 01. - 2005. 08. -12,774 0.827 6,389 0.323 -19,162 0.721 0.19 0.479
  Before 2003. 12.        
 3-6 Months Before Death After 2009. 12. 1,464,197 <.0001 -532,992 <.0001 1,997,189 <.0001 4.66 <.0001
  2005.09. - 2009. 11. 1,233,171 <.0001 -274,767 <.0001 1,507,939 <.0001 3.56 <.0001
  2004. 01. - 2005. 08. 113,641 0.135 6,551 0.463 107,090 0.119 0.13 0.76
  Before 2003. 12.        
 6-9 Months Before Death After 2009. 12. 1,030,289 <.0001 -522,297 <.0001 1,552,586 <.0001 1.81 0.034
  2005.09. - 2009. 11. 833,465 <.0001 -288,461 <.0001 1,121,9 6 <.0001 1.36 0.017
  2004. 01. - 2005. 08. 55,123 0.486 5,955 0.534 49,168 0.49 -0.37 0.406
  Before 2003. 12.        
 9-12 Months Before Death After 2009. 12. 743,463 <.0001 -547,043 <.0001 1,290,506 <.0001 2.07 0.033
  2005.09. - 2009. 11. 640,257 <.0001 -306,763 <.0001 947,020 <.0001 1.32 0.039
  2004. 01. - 2005. 08. 62,382 0.48 10,426 0.333 51,957 0.513 -0.07 0.883
  Before 2003. 12.        
Outpatient 3 Month Before Death After 2009. 12. 265,423 <.0001 -235,586 <.0001 501,009 <.0001 2.19 <.0001
  2005.09. - 2009. 11. 434,482 <.0001 -163,069 <.0001 597,551 <.0001 2.05 <.0001
  2004. 01. - 2005. 08. 113,662 <.0001 -98,619 <.0001 212,282 <.0001 0.56 <.0001
  Before 2003. 12.        
 3-6 Months Before Death After 2009. 12. 657,593 <.0001 -329,169 <.0001 986,762 <.0001 3.63 <.0001
  2005.09. - 2009. 11. 853,518 <.0001 -225,690 <.0001 1,079,208 <.0001 3.21 <.0001
  2004. 01. - 2005. 08. 233,566 <.0001 -135,484 <.0001 369,049 <.0001 0.92 <.0001
  Before 2003. 12.        
 6-9 Months Before Death After 2009. 12. 489,635 <.0001 -383,432 <.0001 873,067 <.0001 2.45 <.0001
  2005.09. - 2009. 11. 772,803 <.0001 -265,974 <.0001 1,038,777 <.0001 2.43 <.0001
  2004. 01. - 2005. 08. 192,842 <.0001 -160,037 <.0001 352,879 <.0001 0.62 <.0001
  Before 2003. 12.        
 9-12 Months Before Death After 2009. 12. 343,838 <.0001 -415,644 <.0001 759,482 <.0001 2.51 <.0001
  2005.09. - 2009. 11. 670,247 <.0001 -288,142 <.0001 958,389 <.0001 2.49 <.0001
  2004. 01. - 2005. 08. 141,017 0.003 -169,862 <.0001 310,879 <.0001 0.85 <.0001
  Before 2003. 12.        
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as inpatient coverage expanded. Of course, copayments 
significantly decreased by three-month intervals. Policy 
periods including outpatient coverage expansion only 
(2004.01.-2005.08.), however, did not affect inpatient 
costs. Since inpatient coverage was expanded, length of 
stay significantly increased in all three month intervals. 
Copayment reduction was greatest in patients hospitalized 
during the three months before death. Outpatient model 
results are presented that demonstrate increases in total 
costs and payer costs as coverage expanded and the 
copayments significantly decreased. More coverage 
expansion was associated with greater copayment 
reductions. Likewise, inpatient length of stay, outpatient 
days increased as coverage expanded. In both inpatient 
and outpatient, three to six month intervals were associated 
with the highest costs and length of stay, and of outpatient 
days as well.
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Discussion
In this study, we examined the association of cancer 
coverage expansion policies on individual patient 
overall healthcare spending, copayments, payer costs, 
and utilizations measured by inpatient length of stay and 
outpatient days. The nationwide dataset over the decade 
used for the study included all lung cancer patients within 
the national health insurance program. The different health 
insurance coverage expansion policy initiatives were used 
to compare health care spending and utilization with three 
month intervals up to a year before death.
Most patients were hospitalized in their end-of-life 
period, especially in last three months before death. 
Most inpatient spending occurred in that period as well. 
Regarding the impact of insurance coverage expansion 
policies, patients were more likely to use inpatient and 
outpatient services as coverage expanded, hence overall 
healthcare spending increased due to higher utilization in 
lung cancer patients (You et al., 2013). In Korea, there are 
no restrictions on using primary, secondary, and tertiary 
medical institutions, and no penalties for repeated care. 
Without referrals for inpatient services, more services 
might be induced to both patients and providers (Park 
and Jang, 2012). 
Although this study found evidence that the financial 
burdens significantly decreased as coverage expanded, 
utilization and spending increased. To prevent escalating 
health service use, we recommend considering policy 
changes for government agencies to maintain budget 
viability for the national health insurance program. First, a 
copayment flat rate might be the most attractive incentive 
for patients who make unnecessary outpatient visits and/
or inpatient hospitalizations. This is also a great incentive 
to providers who are providing excessive unnecessary, 
expensive, and advanced tech services. The lessons from 
other studies show that increased cost-sharing decreases 
health care utilization (Leibowitz et al., 1985; Lohr et al., 
1986; Newhouse, 2004). Different rate of copayments 
could be applied depending on types of cancer, years of 
cancer treatment period, cancer stage at diagnosis and 
costs of various health services. This strategy could help 
controlling the moral hazard of both patient and providers 
as well. 
Escalating healthcare costs caused by unnecessary 
utilization might be controlled by fixing reimbursement 
of annual copayments dependent on severity of cancer 
progression. Since payment is based on FFS in Korea, 
patients and providers lack incentives to reduce utilization. 
Government agencies alone can act to gauge national 
spending levels based on patient’s severity, types, and 
patterns of care, then set reasonable episode copayments 
limitations.
Demand for private health insurance plans by NHI 
members, which broadly cover medical expenses caused 
by catastrophic illness and accidents, is driven by the 
limited coverage and weak financial protection from the 
NHI benefit package (Shin, 2012). Private health insurance 
plans are both supplementary and complementary to 
the NHI plan by paying a lump-sum disbursement upon 
diagnosis of critical illness irrespective of actual medical 
bills and the receipt of care, or by providing itemized 
medical expenses compensation upon service use (Shin, 
2012). Since economically vulnerable populations are 
less likely to have private health insurance to cover their 
cancer treatment costs, different levels of coverage rate 
should be implemented based on socio-economic status, 
especially depending on possession of private insurance 
among NHI members.
Government agencies also need to focus on more 
on prevention, not just expanding coverage. Since the 
landmark reports showing that smoking causes lung 
cancer over a half century ago (Doll and Hill, 1954; U.S. 
Department of Health Education and Welfare, 1964), 
expansion of smoking cessation programs should be first 
implemented. Furthermore, as our study confirmed, a large 
portion of healthcare spending occurs in the very end-
of-life, so attention should be paid to palliative care, and 
development and expansion of facilities such as hospices 
that specialize in end of life care. 
This study has several limitations worth noting, and 
caution must be taken when interpreting the study’s results 
or attempting to generalize its findings. Although we 
analyzed nationwide all inpatient and outpatient insurance 
claims for lung cancer during a defined period, South 
Korea’s unique health care delivery and insurance system 
may significantly limit generalizability of the results of 
this study. Costs of care or rates of copayments are likely 
to depend upon the type of health insurance system in 
place and the ability of health care providers to negotiate 
the price of medical services.
Furthermore, we investigated only lung cancer 
patients. Therefore, our results will differ from spending 
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and utilizations of other cancer patients, and this could 
weaken the reliability of our findings. A lack of data 
with which to analyze important aspects of patient care 
quality was another limitation of our study. Our study 
also suffered because it lacked non-insurance covered 
services information, one of the most important cost 
factors. Given the nature of claims dataset, this study 
artificially calculated the progression of cancer. Further 
research using cohort datasets should be performed to 
inform the association examined in this study controlling 
for proper severity. Lastly, advances in level of treatment 
and medical technology for lung cancer might increase 
utilization and spending. Further studies are needed to 
examine the associations among treatments, technology 
advancement and patient outcome.
Although several limitations are presented, to the best 
of our knowledge, this is the one of few evaluations of 
the impact of copayment policies on healthcare spending 
and utilization measures in South Korea. We believe 
our findings will prove useful to health policy makers, 
especially those residing in countries with national health 
insurance programs based on fee-for-service payments. 
Our findings add to mounting evidence of the need to 
develop a national cancer management strategy.
In conclusions, our retrospective cohort design study 
showed that cancer copayments policies over a decade in 
South Korea reduced patient burdens for both inpatient 
and outpatient health care services, although more burden 
was shifted to the NHI and overall healthcare costs. As 
coverage for cancer expanded, utilization measured 
by inpatient LOS and outpatient days also increased, 
suggesting that moral hazard might have been important 
in lung cancer patients. Furthermore, significant cost 
increases suggest that more expensive, technologically 
advanced treatments or diagnosis services were offered 
as coverage expanded. Lastly, this study suggests that the 
practice pattern within a hospital might be influenced by 
coverage policy. Health policy makers should consider 
initiating health policies to influence long-term outcomes 
of services performance and overall healthcare spending 
and utilization.
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